Trial Profile
A Phase 2b/3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo in Japanese Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 01 Jul 2022
Price :
$35
*
At a glance
- Drugs Upadacitinib (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms SELECT-SUNRISE
- Sponsors AbbVie
- 09 Jun 2022 Status changed from active, no longer recruiting to completed.
- 15 Dec 2020 Planned End Date changed from 14 Jan 2022 to 4 Jun 2022.
- 11 Apr 2020 Results published in the Rheumatology